WorkBoat Header Background Image

WorkBoat+ Membership – Free to Join

Thank you for another great WorkBoat Show! We hope to see everyone back in New Orleans December 2–4, 2026. Save the date!

Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aptevo Therapeutics Inc. - Common Stock (NQ:APVO)

0.5799 -0.3502 (-37.65%)
Streaming Delayed Price Updated: 11:31 AM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aptevo Therapeutics Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Aptevo Therapeutics Announces Publication of a Scientific Article in Peer-Reviewed Journal, Frontiers in Aging
Lead Clinical Candidate, APVO436, Recently Showed Clinical Activity and Acceptable Safety Profile in Adults with Myelodysplastic Syndrome (MDS) Article outlines a new strategy to employ APVO436 for... 
From Aptevo Therapeutics
Via AccessWire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Gainers Regencell Bioscience (NASDAQ:RGC)... 
Via Benzinga
News headline image
Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Phase 1 study showed some patients with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) achieved a remission with APVO436 after failing 1-8 lines of prior therapies - Data was... 
From Aptevo Therapeutics
Via AccessWire
News headline image
Aptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights
SEATTLE, WA / ACCESSWIRE / August 12, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology... 
From Aptevo Therapeutics
Via AccessWire
News headline image
Aptevo Therapeutics' Chief Scientific Officer, Jane Gross, PhD, to Present at Upcoming Cambridge Health Institute PEGS Virtual Conference
SEATTLE, WA / ACCESSWIRE / July 16, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on... 
From Aptevo Therapeutics
Via AccessWire
News headline image
Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index
SEATTLE, WA / ACCESSWIRE / June 29, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on... 
From Aptevo Therapeutics
Via AccessWire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers Anavex Life Sciences (NASDAQ:AVXL) stock increased by 17.07% to $25.92 during Tuesday's regular session. As of 12:33 EST, this security is trading at a volume... 
Via Benzinga
News headline image
48 Biggest Movers From Yesterday ↗
Gainers Lydall, Inc. (NYSE: LDL) shares jumped 85.4% to close at $61.72 on Monday after the company agreed to be acquired by Unifrax for $61.10 per share. New Concept Energy,... 
Via Benzinga
News headline image
Mid-Afternoon Market Update: Dow Jumps Over 500 Points; Lydall Shares Spike Higher ↗
Toward the end of trading Monday, the Dow traded up 1.71% to 33,857.87 while the NASDAQ rose 0.63% to 14,119.16. The S&P also rose, gaining 1.28% to 4,219.92. The U.S. has the... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers Anavex Life Sciences (NASDAQ:AVXL) shares moved upwards by 17.07% to $25.92 during Monday's regular session. Anavex Life Sciences's stock is trading at a... 
Via Benzinga
News headline image
31 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Lydall, Inc. (NYSE: LDL) shares climbed 82.3% to $60.68 after the company agreed to be acquired by Unifrax for $61.10 per share. Raven Industries, Inc. (NASDAQ: RAVN)... 
Via Benzinga
News headline image
Mid-Morning Market Update: Markets Open Higher; CNH Industrial To Buy Raven Industries ↗
Following the market opening Monday, the Dow traded up 1.27% to 33,712.27 while the NASDAQ rose 0.32% to 14,075.68. The S&P also rose, gaining 0.87% to 4,202.85. The U.S. has... 
Via Benzinga
Topics Stocks
News headline image
Aptevo Therapeutics Insights: Return On Capital Employed ↗
In Q1, Aptevo Therapeutics (NASDAQ:APVO) posted sales of $2.42 million. Earnings were up 1.01%, but Aptevo Therapeutics still reported an overall loss of $6.89 million. In Q4,... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers Clearside Biomedical (NASDAQ:CLSD) stock moved upwards by 26.21% to $3.81 during Tuesday's regular session. As of 12:30 EST, this security is trading at a... 
Via Benzinga
News headline image
Looking Into Aptevo Therapeutics's Return On Capital Employed ↗
During Q1, Aptevo Therapeutics's (NASDAQ:APVO) reported sales totaled $2.42 million. Despite a 1.01% in earnings, the company posted a loss of $6.89 million. In Q4, Aptevo... 
Via Benzinga
News headline image
Aptevo Therapeutics Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436 in Adult Patients with Acute Myeloid Leukemia
Initiates Multi-Center, Multi-Arm Trial Using Active Dose Identified in the Dose Escalation Phase of the Trial SEATTLE, WA / ACCESSWIRE / May 27, 2021 / Aptevo Therapeutics Inc. ("Aptevo")... 
From Aptevo Therapeutics
Via AccessWire
News headline image
Aptevo Stock Gains on Encouraging Single-Agent Activity for APVO436 In Leukemia Patients ↗
Aptevo Therapeutics Inc (NASDAQ: APVO) has announced positive results from Phase 1 dose-escalation trial evaluating lead ADAPTIR candidate, APVO436, for acute... 
Via Benzinga
News headline image
Aptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid Leukemia
- Dose Escalation Study of APVO436 Shows Favorable Safety Profile and No Severe Neutropenia, a Potentially Life-threatening Side Effect, Reported in a Significant Number of Patients Receiving... 
From Aptevo Therapeutics
Via AccessWire
Topics Death Intellectual Property
News headline image
Aptevo Therapeutics Reports First Quarter 2021 Financial Results
Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Dosing in Cohort 10 Ongoing SEATTLE, WA / ACCESSWIRE / May 11, 2021 / Aptevo... 
From Aptevo Therapeutics
Via AccessWire
News headline image
Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting
SEATTLE, WA / ACCESSWIRE / April 9, 2021 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its... 
From Aptevo Therapeutics
Via AccessWire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Privacy Policy DSAR Requests Terms of Use Locations Events, Products & Services
© 2025 Diversified Communications. All rights reserved.